Research has demonstrated that genetic polymorphisms within the ADAM33 locus are correlated with an increased susceptibility to bronchial disorders, notably asthma (Deng et al. 2017), and this gene also represents a potential biomarker for inflammation and a viable therapeutic target in individuals afflicted with chronic obstructive pulmonary disease (Fachri et al. 2021). The gene discussed is ADAM33; the disease is asthma.